Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer, January 2022

Free Subscription


Abstracts

Retrieve all available abstracts of the following 343 articles:
HTML format


 

Single Articles

  1. PAVLOV VN, Urmantsev MF, Yudina YB, Bakeev MP, et al
    [A place of robot-assisted cystectomy in treatment of muscle-invasive bladder cancer].
    Urologiia. 2021;:141-144.
    PubMed    
    Abstract available

  2. PEMOV A, Wegman-Ostrosky T, Kim J, Koutros S, et al
    Identification of Genetic Risk Factors for Familial Urinary Bladder Cancer: An Exome Sequencing Study.
    JCO Precis Oncol. 2021;5.
    PubMed    
    Abstract available

  3. FU M, Klose C, Sparks A, Whalen M, et al
    Impact of Variant Histology on Occult Nodal Metastasis after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Review of the National Cancer Database.
    Clin Genitourin Cancer. 2021 Dec 1. pii: S1558-7673(21)00226.
    PubMed    
    Abstract available

  4. REN W, Hu J, Li H, Chen J, et al
    miR-616-5p Promotes Invasion and Migration of Bladder Cancer via Downregulating NR2C2 Expression.
    Front Oncol. 2021;11:762946.
    PubMed    
    Abstract available

  5. TANABE S, Sugino S, Niiya K, Ichida K, et al
    A Case of Incidental Detection of Asymptomatic Bladder Cancer by Transvaginal Ultrasound.
    Cureus. 2021;13:e20451.
    PubMed    
    Abstract available

  6. TANG W, Niu H, Yang Y, Li H, et al
    Efficacy and safety of transurethral resection of bladder tumor for superficial bladder cancer.
    Am J Transl Res. 2021;13:12860-12867.
    PubMed    
    Abstract available

  7. MA X, Wen Y, Wang Y, Zhang M, et al
    Linc00662 plays an oncogenic role in bladder cancer by sponging miR-199a-5p.
    Am J Transl Res. 2021;13:12673-12683.
    PubMed    
    Abstract available

  8. FABIANO E, Riou O, Pointreau Y, Perichon N, et al
    Role of radiotherapy in the management of bladder cancer: Recommendations of the French society for radiation oncology.
    Cancer Radiother. 2021 Dec 23. pii: S1278-3218(21)00295.
    PubMed    
    Abstract available

  9. ZHANG X, Ma X, Wang Q, Kong Z, et al
    EZH2 targeting to improve the sensitivity of acquired radio-resistance bladder cancer cells.
    Transl Oncol. 2021;16:101316.
    PubMed    
    Abstract available

  10. HAN C, Wang Z, Chen S, Li L, et al
    Erratum to "Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-kappaB Axis".
    Oxid Med Cell Longev. 2021;2021:9857803.
    PubMed    
    Abstract available

  11. ADAMCZYK P, Kadlubowski M, Poblocki P, Adamowicz J, et al
    Age and risk of major complications in patients undergoing radical cystectomy for muscle invasive bladder cancer.
    Wideochir Inne Tech Maloinwazyjne. 2021;16:722-727.
    PubMed    
    Abstract available

  12. LU M, Zhan H, Liu B, Li D, et al
    N6-methyladenosine-related non-coding RNAs are potential prognostic and immunotherapeutic responsiveness biomarkers for bladder cancer.
    EPMA J. 2021;12:589-604.
    PubMed    
    Abstract available

  13. FLETCHER SA, Bivalacqua TJ, Brawley OW, Kates M, et al
    Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer.
    Urol Oncol. 2021 Dec 20. pii: S1078-1439(21)00514.
    PubMed    
    Abstract available

  14. LIU T, Jiang G
    A systematic review and meta-analysis of neoadjuvant chemotherapy for bladder cancer between ddMVAC and GC regimen.
    Urol Oncol. 2021 Dec 20. pii: S1078-1439(21)00515.
    PubMed    
    Abstract available

  15. LEMINSKI A, Kaczmarek K, Bancarz A, Zakrzewska A, et al
    Educational and Psychological Support Combined with Minimally Invasive Surgical Technique Reduces Perioperative Depression and Anxiety in Patients with Bladder Cancer Undergoing Radical Cystectomy.
    Int J Environ Res Public Health. 2021;18.
    PubMed    
    Abstract available

  16. NEDJADI T, Albarakati N, Benabdelkamel H, Masood A, et al
    Proteomic Profiling of Plasma-Derived Biomarkers in Patients with Bladder Cancer: A Step towards Clinical Translation.
    Life (Basel). 2021;11.
    PubMed    
    Abstract available

  17. D'ALOIA A, Arrigoni E, Costa B, Berruti G, et al
    RalGPS2 Interacts with Akt and PDK1 Promoting Tunneling Nanotubes Formation in Bladder Cancer and Kidney Cells Microenvironment.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  18. THAM SM, Rahmat JN, Chiong E, Wu Q, et al
    Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with GMCSF+IFN alpha Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model.
    Biomedicines. 2021;9.
    PubMed    
    Abstract available

  19. CONSTANTIN T, Pavalean M, Bucur S, Constantin MM, et al
    Animal Models in Bladder Cancer.
    Biomedicines. 2021;9.
    PubMed    
    Abstract available

  20. RANA V, Parama D, Khatoon E, Girisa S, et al
    Reiterating the Emergence of Noncoding RNAs as Regulators of the Critical Hallmarks of Gall Bladder Cancer.
    Biomolecules. 2021;11.
    PubMed    
    Abstract available

  21. YAMASHITA S, Iwahashi Y, Miyai H, Matsumura N, et al
    Usefulness of Preoperative High Systemic Immune-Inflammation Index as a Prognostic Biomarker in Patients Who Undergo Radical Cystectomy for Bladder Cancer: Multicenter Analysis.
    Diagnostics (Basel). 2021;11.
    PubMed    
    Abstract available

  22. LAUKHTINA E, Schuettfort VM, D'Andrea D, Pradere B, et al
    Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
    Mol Carcinog. 2022;61:5-18.
    PubMed    
    Abstract available

  23. NA L, Wang Z, Bai Y, Sun Y, et al
    WNT7B represses epithelial-mesenchymal transition and stem-like properties in bladder urothelial carcinoma.
    Biochim Biophys Acta Mol Basis Dis. 2022;1868:166271.
    PubMed    
    Abstract available

  24. SHEU ZL, Huang CP, Chang CH, Chen CH, et al
    Tumor distribution affects bladder recurrence but not survival outcome of multifocal upper tract urothelial carcinoma treated with radical nephroureterectomy.
    Sci Rep. 2021;11:19059.
    PubMed    
    Abstract available

  25. GHASEMI H, Mousavibahar SH, Hashemnia M, Karimi J, et al
    Transitional cell carcinoma matrix stiffness regulates the osteopontin and YAP expression in recurrent patients.
    Mol Biol Rep. 2021;48:4253-4262.
    PubMed    
    Abstract available

  26. MINERVINI A, Di Maida F, Tasso G, Mari A, et al
    Robot assisted radical cystectomy with Florence robotic intracorporeal neobladder (FloRIN): Analysis of survival and functional outcomes after first 100 consecutive patients upon accomplishment of phase 3 IDEAL framework.
    Eur J Surg Oncol. 2021;47:2651-2657.
    PubMed    
    Abstract available

  27. MICHEL KF, Spaulding A, Jemal A, Yabroff KR, et al
    Associations of Medicaid Expansion With Insurance Coverage, Stage at Diagnosis, and Treatment Among Patients With Genitourinary Malignant Neoplasms.
    JAMA Netw Open. 2021;4:e217051.
    PubMed    
    Abstract available

  28. LOPEZ-BELTRAN A, Cimadamore A, Montironi R, Cheng L, et al
    Molecular pathology of urothelial carcinoma.
    Hum Pathol. 2021;113:67-83.
    PubMed    
    Abstract available

  29. ZANCHETTIN C, Zanella L, Zoffoli G, Venturini A, et al
    Ultra-rapid regrowth of urothelial cardiac metastasis after debulking surgery.
    Cardiovasc Pathol. 2021;53:107334.
    PubMed    
    Abstract available

  30. WANG Y, Ju L, Guo Z, Qian K, et al
    Pedigree analysis of a POLD1 germline mutation in urothelial carcinoma shows a close association between different mutation burdens and overall survival.
    Cell Mol Immunol. 2021;18:767-769.
    PubMed    


  31. KATAYAMA S, Schuettfort VM, Pradere B, Mori K, et al
    Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer.
    J Cancer Res Clin Oncol. 2022 Jan 8. pii: 10.1007/s00432-021-03887.
    PubMed    
    Abstract available

  32. TSE RT, Zhao H, Wong CY, Kong AW, et al
    In vitro assessment of intra-operative and post-operative environment in reducing bladder cancer recurrence.
    Sci Rep. 2022;12:22.
    PubMed    
    Abstract available

  33. BOUCHELOUCHE K
    PET/CT in Bladder Cancer: An Update.
    Semin Nucl Med. 2022 Jan 4. pii: S0001-2998(21)00105.
    PubMed    
    Abstract available

  34. YU XY, Ma CQ, Sheng YH
    circRNA CRIM1 regulates the migration and invasion of bladder cancer by targeting miR182/Foxo3a axis.
    Clin Transl Oncol. 2022 Jan 7. pii: 10.1007/s12094-021-02768.
    PubMed    
    Abstract available

  35. MASTRI M, Ramakrishnan S, Shah SD, Karasik E, et al
    Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartment.
    Am J Clin Exp Urol. 2021;9:416-434.
    PubMed    
    Abstract available

  36. DAVIS L, Isali I, Prunty M, Calaway A, et al
    Female Sexual Function Following Radical Cystectomy in Bladder Cancer.
    Sex Med Rev. 2022 Jan 3. pii: S2050-0521(21)00090.
    PubMed    
    Abstract available

  37. LI P, Li L, Li Z, Wang S, et al
    Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway.
    Cancer Cell Int. 2022;22:7.
    PubMed    
    Abstract available

  38. ALAM SM, Chollet-Hinton L, Thompson J, Holzbeierlein JM, et al
    Effect of prior radiation on stage, differentiation, and survival in bladder cancer.
    World J Urol. 2022 Jan 6. pii: 10.1007/s00345-021-03901.
    PubMed    
    Abstract available

  39. CHEN K, Xing J, Yu W, Xia Y, et al
    Identification and Validation of Hub Genes Associated with Bladder Cancer by Integrated Bioinformatics and Experimental Assays.
    Front Oncol. 2021;11:782981.
    PubMed    
    Abstract available

  40. LIU X, Xu A, Huang J, Shen H, et al
    Effective prediction model for preventing postoperative deep vein thrombosis during bladder cancer treatment.
    J Int Med Res. 2022;50:3000605211067688.
    PubMed    
    Abstract available

  41. MA J, Vaishnani DK, Lin R, Lyu J, et al
    Artificial intelligence in bladder cancer: current trends and future possibilities.
    Chin Med J (Engl). 2022 Jan 4. pii: 00029330-900000000-98223.
    PubMed    


  42. OKUNEYE K, Bergman D, Bloodworth JC, Pearson AT, et al
    A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer.
    Comput Syst Oncol. 2021;1.
    PubMed    
    Abstract available

  43. WAN P, Chen Z, Huang M, Jiang H, et al
    miR-200a-3p facilitates bladder cancer cell proliferation by targeting the A20 gene.
    Transl Androl Urol. 2021;10:4262-4274.
    PubMed    
    Abstract available

  44. TENG X, Liu Y, Wang L, Wang G, et al
    Lidocaine exerts anticancer activity in bladder cancer by targeting isoprenylcysteine carboxylmethyltransferase (ICMT).
    Transl Androl Urol. 2021;10:4219-4230.
    PubMed    
    Abstract available

  45. CHEN C, Huang Z, Huang P, Li K, et al
    Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer.
    BMC Microbiol. 2022;22:7.
    PubMed    
    Abstract available

  46. FATTAHI MJ, Haghshenas MR, Ghaderi A
    Immunometabolism in bladder cancer microenvironment.
    Endocr Metab Immune Disord Drug Targets. 2022 Jan 4. pii: EMIDDT-EPUB-119930.
    PubMed    
    Abstract available

  47. REIS LO, Dal Col LSB, Capibaribe DM, de Mendonca GB, et al
    Presence and predominance of histological grade 3 define cT1HG bladder cancer prognostic groups.
    Investig Clin Urol. 2022;63:21-26.
    PubMed    
    Abstract available

  48. LEE S, Oh YT, Kim HM, Jung DC, et al
    Imaging Patterns of Bacillus Calmette-Guerin-Related Granulomatous Prostatitis Based on Multiparametric MRI.
    Korean J Radiol. 2022;23:60-67.
    PubMed    
    Abstract available

  49. FAVARO WJ, Socca EAR, Bockelmann PK, Reis IB, et al
    Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model.
    Med Oncol. 2022;39:24.
    PubMed    
    Abstract available

  50. LIU Q
    The emerging roles of exosomal long non-coding RNAs in bladder cancer.
    J Cell Mol Med. 2022 Jan 3. doi: 10.1111/jcmm.17152.
    PubMed    
    Abstract available

  51. DA Z, Huo Z, Luo HH, Liao RQ, et al
    [Clinicopathological Analysis of Brain Metastatic Carcinoma in Tibet].
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021;43:869-874.
    PubMed    
    Abstract available

  52. ZHUANG J, Hao J, Bu F, Yin H, et al
    MicroRNA-582-5p regulates cell invasion in bladder cancer through targeting Forkhead Box G1.
    Pathol Res Pract. 2021;230:153752.
    PubMed    
    Abstract available

  53. YACOUBA A, Alou MT, Lagier JC, Dubourg G, et al
    Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens.
    Semin Cancer Biol. 2021 Dec 31. pii: S1044-579X(21)00303.
    PubMed    
    Abstract available

  54. GHASSEMI H, Hashemnia M, Mousavibahar SH, Mahmoodzadeh Hosseini H, et al
    Positive Association of Matrix Proteins Alteration with TAZ and The Progression of High-Grade Bladder Cancer.
    Cell J. 2021;23:742-749.
    PubMed    
    Abstract available

  55. HEMISSI I, Boussetta S, Dallali H, Hellal F, et al
    Correction to: Development of a custom next-generation sequencing panel for the determination of bladder cancer risk in a Tunisian cohort.
    Mol Biol Rep. 2022 Jan 2. pii: 10.1007/s11033-021-07052.
    PubMed    


  56. HUANG Z, Liu J, Yang J, Yan Y, et al
    PDE4B Induces Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Is Transcriptionally Suppressed by CBX7.
    Front Cell Dev Biol. 2021;9:783050.
    PubMed    
    Abstract available

  57. SZYMANKIEWICZ M, Kamecki K, Jarzynka S, Koryszewska-Baginska A, et al
    Case Report: Echinocandin-Resistance Candida glabrata FKS Mutants From Patient Following Radical Cystoprostatectomy Due to Muscle-Invasive Bladder Cancer.
    Front Oncol. 2021;11:794235.
    PubMed    
    Abstract available

  58. XU Y, Chen D, Shen L, Huang X, et al
    Identification and Mechanism of the PD-1/PD-L1 Genomic Signature SORL1 as Protective Factor in Bladder Cancer.
    Front Genet. 2021;12:736158.
    PubMed    
    Abstract available

  59. LIU Z, Qi T, Li X, Yao Y, et al
    A Novel TGF-beta Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Front Immunol. 2021;12:791924.
    PubMed    
    Abstract available

  60. LI B, Xiao Q, Shan L, Song Y, et al
    NCAPH promotes cell proliferation and inhibits cell apoptosis of bladder cancer cells through MEK/ERK signaling pathway.
    Cell Cycle. 2022 Jan 2:1-12. doi: 10.1080/15384101.2021.2021050.
    PubMed    
    Abstract available

  61. NAUMAN M, Hasan AS, Sultan G, Kumar P, et al
    Inflammatory myofibroblastic tumour of genitourinary system.
    J Pak Med Assoc. 2021;71:2467-2469.
    PubMed    
    Abstract available

  62. RAVINDRANATHAN D, Alhalabi O, Rafei H, Shah AY, et al
    Landscape of Immunotherapy in Genitourinary Malignancies.
    Adv Exp Med Biol. 2021;1342:143-192.
    PubMed    
    Abstract available

  63. ISHIYAMA Y, Kondo T, Tachibana H, Ishihara H, et al
    Association Between Anesthetic Technique and Survival After Radical Nephroureterectomy: A Propensity Score-matching Study.
    In Vivo. 2022;36:458-464.
    PubMed    
    Abstract available

  64. XIANG P, Du Z, Hao Y, Guan D, et al
    Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.
    Front Oncol. 2021;11:784627.
    PubMed    
    Abstract available

  65. TALWAR HS, Panwar VK, Mittal A, Ghorai RP, et al
    Successful management of a high-output urinary fistula following radical cystectomy and ileal conduit: a conservative approach.
    BMJ Case Rep. 2021;14.
    PubMed    
    Abstract available

  66. SCHULE J, Kraus F, Veil C, Kunkel S, et al
    Multi-Physical Tissue Modeling of a Human Urinary Bladder.
    Annu Int Conf IEEE Eng Med Biol Soc. 2021;2021:4297-4302.
    PubMed    
    Abstract available

  67. YANAGISAWA T, Mori K, Katayama S, Mostafaei H, et al
    Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis.
    Int J Clin Oncol. 2022;27:59-71.
    PubMed    
    Abstract available

  68. ISOBE T, Naiki T, Sugiyama Y, Naiki-Ito A, et al
    Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
    Int J Clin Oncol. 2022;27:165-174.
    PubMed    
    Abstract available

  69. SHIMIZU R, Honda M, Teraoka S, Yumioka T, et al
    Sarcopenia is associated with survival in patients with urothelial carcinoma treated with systemic chemotherapy.
    Int J Clin Oncol. 2022;27:175-183.
    PubMed    
    Abstract available

  70. SHIGIHARA K, Shimonohara N, Stanley BJ
    Outcome of a dog with urinary bladder osteosarcoma treated with a total cystectomy and ureterocutaneostomy.
    Can Vet J. 2021;62:1089-1094.
    PubMed    
    Abstract available

  71. LI X, Wei Z, Yu H, Xu Y, et al
    Secretory autophagy-induced bladder tumour-derived extracellular vesicle secretion promotes angiogenesis by activating the TPX2-mediated phosphorylation of the AURKA-PI3K-AKT axis.
    Cancer Lett. 2021;523:10-28.
    PubMed    
    Abstract available

  72. GAO H, Chen J, Li G, Cui X, et al
    Pediatric laparoscopic partial cystectomy for the treatment of benign bladder tumors and urachal cysts.
    BMC Urol. 2021;21:128.
    PubMed    
    Abstract available

  73. OSHINA T, Taguchi S, Miyakawa J, Akiyama Y, et al
    Clinicopathological features and oncological outcomes of urothelial carcinoma involving the ureterovesical junction.
    Jpn J Clin Oncol. 2022;52:65-72.
    PubMed    
    Abstract available

  74. DURANTE J, Manassero F, Fidecicchi T, Tognarelli A, et al
    Autologous fascial slings remain viable at long-term follow-up: a post cystectomy case report.
    BMC Urol. 2021;21:122.
    PubMed    
    Abstract available

  75. HO SR, Lee YC, Ittmann MM, Lin FT, et al
    RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis.
    Cancer Lett. 2021;520:344-360.
    PubMed    
    Abstract available

  76. MIYASAKA Y, Kawamura H, Sato H, Kubo N, et al
    Carbon ion radiotherapy for prostate cancer with bladder invasion.
    BMC Urol. 2021;21:106.
    PubMed    
    Abstract available

  77. TU X, Zhang N, Zhuang X, Chen S, et al
    Incidental diagnosis of nonfunctional bladder paraganglioma: a case report and literature review.
    BMC Urol. 2021;21:98.
    PubMed    
    Abstract available

  78. PRUITT SL, Gerber DE, Zhu H, Heitjan DF, et al
    Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer.
    Cancer Med. 2021;10:4752-4767.
    PubMed    
    Abstract available

  79. SHIMOHAMA S, Oki K, Narita H, Mashima K, et al
    Trousseau's Syndrome Presenting as Multiple Cerebral Infarctions Caused by Mucin-producing Bladder Micropapillary Urothelial Cancer.
    Intern Med. 2022;61:97-101.
    PubMed    
    Abstract available

  80. MOHANTY SK, Mishra SK, Tiwari A, Sharma S, et al
    Reappraisal of HER2 Amplification in High-Grade Urothelial Carcinoma Based on 2018 ASCO/CAP Clinical Practice Guidelines.
    Am J Clin Pathol. 2021;156:1130-1141.
    PubMed    
    Abstract available

  81. STERN ES, Siddiqui MT
    Nuclear hypochromasia: Shedding light on the "lightness" of high-grade urothelial carcinoma.
    Diagn Cytopathol. 2021;49:1032-1035.
    PubMed    
    Abstract available

  82. TODENHOFER T, Gibb EA, Seiler R, Kamyabi A, et al
    Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma.
    Urol Oncol. 2021;39:498.
    PubMed    
    Abstract available

  83. BELLAMRI M, Brandt K, Brown CV, Wu MT, et al
    Cytotoxicity and genotoxicity of the carcinogen aristolochic acid I (AA-I) in human bladder RT4 cells.
    Arch Toxicol. 2021;95:2189-2199.
    PubMed    
    Abstract available

  84. LAUKHTINA E, Pradere B, Mori K, Schuettfort VM, et al
    Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review.
    Urol Oncol. 2021;39:471-479.
    PubMed    
    Abstract available

  85. GOTO T, Miyamoto H
    The Role of Estrogen Receptors in Urothelial Cancer.
    Front Endocrinol (Lausanne). 2021;12:643870.
    PubMed    
    Abstract available

  86. NAYYAR R, Saini S, Sharma A, Kurra S, et al
    Systemic dissemination of tumor cells during transurethral resection in patients with bladder tumor and its clinical relevance: A follow up study.
    Urol Oncol. 2021;39:497.
    PubMed    
    Abstract available

  87. KERROUMI S, Neuzillet Y, Soorojebally Y, Radulescu C, et al
    The impact of carcinoma in situ in ureteral margins during radical cystectomy: A case-controlled study.
    Urol Oncol. 2021;39:497.
    PubMed    
    Abstract available

  88. DIAMANTOPOULOS LN, Sekar RR, Holt SK, Khaki AR, et al
    Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy.
    Urol Oncol. 2021;39:496.
    PubMed    
    Abstract available

  89. SWAMI U, Grivas P, Pal SK, Agarwal N, et al
    Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience.
    Cancer Treat Res Commun. 2021;27:100325.
    PubMed    
    Abstract available

  90. SU X, Lu X, Bazai SK, Comperat E, et al
    Comprehensive integrative profiling of upper tract urothelial carcinomas.
    Genome Biol. 2021;22:7.
    PubMed    
    Abstract available

  91. CHEN CH, Grollman AP, Huang CY, Shun CT, et al
    Additive Effects of Arsenic and Aristolochic Acid in Chemical Carcinogenesis of Upper Urinary Tract Urothelium.
    Cancer Epidemiol Biomarkers Prev. 2021;30:317-325.
    PubMed    
    Abstract available

  92. ASSADI A, Alzubaidi A, Lesmana H, Brennan RC, et al
    Pure Bladder Malignant Rhabdoid Tumor Successfully Treated With Partial Cystectomy, Radiation, and Chemotherapy: A Case Report and Review of the Literature.
    J Pediatr Hematol Oncol. 2021;43:e1214-e1216.
    PubMed    
    Abstract available

  93. LIPETSKAIA L, Lee TG, Li D, Meyer H, et al
    Pelvic Floor Organ Prolapse After Radical Cystectomy in Patients With Uroepithelial Carcinoma.
    Female Pelvic Med Reconstr Surg. 2021;27:e501-e504.
    PubMed    
    Abstract available

  94. QIU Y, Gao Y, Chen C, Xie M, et al
    Deciphering the influence of urinary microbiota on FoxP3+ regulatory T cell infiltration and prognosis in Chinese patients with non-muscle-invasive bladder cancer.
    Hum Cell. 2022 Jan 15. pii: 10.1007/s13577-021-00659.
    PubMed    
    Abstract available

  95. MAO M, Yang L, Hu J, Liu B, et al
    Oncogenic E3 ubiquitin ligase NEDD4 binds to KLF8 and regulates the microRNA-132/NRF2 axis in bladder cancer.
    Exp Mol Med. 2022 Jan 14. pii: 10.1038/s12276-021-00663.
    PubMed    
    Abstract available

  96. YAMASHITA S, Mashima N, Higuchi M, Matsumura N, et al
    Modified 5-Item Frailty Index Score as Prognostic Marker After Radical Cystectomy in Bladder Cancer.
    Clin Genitourin Cancer. 2021 Dec 27. pii: S1558-7673(21)00250.
    PubMed    
    Abstract available

  97. QIU F, Liu Q, Xia Y, Jin H, et al
    Circ_0000658 knockdown inhibits epithelial-mesenchymal transition in bladder cancer via miR-498-induced HMGA2 downregulation.
    J Exp Clin Cancer Res. 2022;41:22.
    PubMed    
    Abstract available

  98. DING H, Huang Y, Shi J, Wang L, et al
    Correction to: Attenuated expression of SNF5 facilitates progression of bladder cancer via STAT3 activation.
    Cancer Cell Int. 2022;22:20.
    PubMed    


  99. PENG G, Guan J, Leng P, Peng L, et al
    Circular RNA circ_0000515 adsorbs miR-542-3p to accelerate bladder cancer progression via up-regulating ILK expression.
    Aging (Albany NY). 2022;14.
    PubMed    
    Abstract available

  100. HAMADA K, Yoshimura K, Oshinomi K, Hirasawa Y, et al
    A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report.
    Medicine (Baltimore). 2022;101:e28339.
    PubMed    
    Abstract available

  101. WEN Z, Huang G, Lai Y, Xiao L, et al
    Diagnostic panel of serum miR-125b-5p, miR-182-5p, and miR-200c-3p as non-invasive biomarkers for urothelial bladder cancer.
    Clin Transl Oncol. 2022 Jan 14. pii: 10.1007/s12094-021-02741.
    PubMed    
    Abstract available

  102. HURST CD, Cheng G, Platt FM, Castro MAA, et al
    Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight.
    Cell Rep Med. 2021;2:100472.
    PubMed    
    Abstract available

  103. BILIM V, Hoshi S
    Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer (NMIBC).
    Clin Case Rep. 2022;10:e05256.
    PubMed    
    Abstract available

  104. ZHU K, Deng W, Deng H, Liu X, et al
    Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.
    PPAR Res. 2021;2021:7056506.
    PubMed    
    Abstract available

  105. YU EY, Stern MC, Jiang X, Tang L, et al
    Family history and risk of bladder cancer: an analysis accounting for first- and second-degree relatives.
    Cancer Prev Res (Phila). 2022 Jan 13. pii: 1940-6207.CAPR-21-0490.
    PubMed    
    Abstract available


  106. Correction: Bladder cancer incidence among workers exposed to o-toluidine, aniline and nitrobenzene at a rubber chemical manufacturing plant.
    Occup Environ Med. 2022;79:e1.
    PubMed    


  107. LIA T, Shao Y, Regmi P, Li X, et al
    Development and validation of Pyroptosisrelated lncRNAs prediction model for bladder cancer.
    Biosci Rep. 2022 Jan 13. pii: 230650. doi: 10.1042/BSR20212253.
    PubMed    
    Abstract available

  108. SCHMIDT B, Velaer KN, Thomas IC, Ganesan C, et al
    Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer.
    Eur Urol Open Sci. 2022;35:29-36.
    PubMed    
    Abstract available

  109. HORIBE Y, Nakata W, Tsujimura G, Tsujimoto Y, et al
    A case of long-term complete remission of locally advanced T4 bladder cancer treated with pembrolizumab.
    Urol Case Rep. 2021;41:101959.
    PubMed    
    Abstract available

  110. KONG N, Chen X, Feng J, Duan T, et al
    Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1.
    Acta Pharm Sin B. 2021;11:4045-4054.
    PubMed    
    Abstract available

  111. YU J, Mao W, Sun S, Hu Q, et al
    Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.
    Cancer Manag Res. 2022;14:67-88.
    PubMed    
    Abstract available

  112. MOHSENZADEGAN M, Razmi M, Vafaei S, Abolhasani M, et al
    Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer.
    Sci Rep. 2022;12:599.
    PubMed    
    Abstract available

  113. SHAH AA, Sun Z, Eom KY, Grajales V, et al
    Treatment disparities in muscle-invasive bladder cancer: Evidence from a large statewide cancer registry.
    Urol Oncol. 2022 Jan 9. pii: S1078-1439(21)00552.
    PubMed    
    Abstract available

  114. ZHAO H, Wu W, Li X, Chen W, et al
    Long noncoding RNA UCA1 promotes glutamine-driven anaplerosis of bladder cancer by interacting with hnRNP I/L to upregulate GPT2 expression.
    Transl Oncol. 2022;17:101340.
    PubMed    
    Abstract available

  115. XU J, Wei L, Liu H, Lei Y, et al
    CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients' Survival.
    Cancer Invest. 2022 Jan 12:1-11. doi: 10.1080/07357907.2022.2028805.
    PubMed    
    Abstract available

  116. LIEDBERG F, Hagberg O, Baseckas G, Brandstedt J, et al
    Anorectal dysfunction after radical cystectomy for bladder cancer.
    Scand J Urol. 2022 Jan 12:1-7. doi: 10.1080/21681805.2021.2025423.
    PubMed    
    Abstract available

  117. HAJJAR M, Rezazadeh A, Naja F, Kardoust Parizi M, et al
    Association of Recommended and Non-Recommended Food Score and Risk of Bladder Cancer: A Case-Control Study.
    Nutr Cancer. 2022 Jan 12:1-8. doi: 10.1080/01635581.2021.2004172.
    PubMed    
    Abstract available

  118. DIANATINASAB M, Forozani E, Akbari A, Azmi N, et al
    Dietary patterns and risk of bladder cancer: a systematic review and meta-analysis.
    BMC Public Health. 2022;22:73.
    PubMed    
    Abstract available

  119. LIU H, Zhang M, Jin H, Tao K, et al
    Fe(III)-Doped Polyaminopyrrole Nanoparticle for Imaging-Guided Photothermal Therapy of Bladder Cancer.
    ACS Biomater Sci Eng. 2022 Jan 11. doi: 10.1021/acsbiomaterials.1c01217.
    PubMed    
    Abstract available

  120. YIN H, Zhang C, Wei Z, He W, et al
    EGF-induced nuclear translocation of SHCBP1 promotes bladder cancer progression through inhibiting RACGAP1-mediated RAC1 inactivation.
    Cell Death Dis. 2022;13:39.
    PubMed    
    Abstract available

  121. DYUGAY IA, Lukyanov DK, Turchaninova MA, Serebrovskaya EO, et al
    Accounting for B-cell behavior and sampling bias predicts anti-PD-L1 response in bladder cancer.
    Cancer Immunol Res. 2022 Jan 10. pii: 2326-6066.CIR-21-0489.
    PubMed    
    Abstract available

  122. RENTSCH CA, Thalmann GN, Lucca I, Kwiatkowski M, et al
    A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guerin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
    Eur Urol Oncol. 2022 Jan 7. pii: S2588-9311(21)00222.
    PubMed    
    Abstract available

  123. RACIOPPI M
    Advances in Management of Bladder Cancer.
    J Clin Med. 2021;11.
    PubMed    
    Abstract available

  124. WRONSKI P, Wronski S, Kurant M, Malinowski B, et al
    Curcumin May Prevent Basement Membrane Disassembly by Matrix Metalloproteinases and Progression of the Bladder Cancer.
    Nutrients. 2021;14.
    PubMed    
    Abstract available

  125. JIMENEZ-GUERRERO R, Belmonte-Fernandez A, Flores ML, Gonzalez-Moreno M, et al
    Wnt/beta-Catenin Signaling Contributes to Paclitaxel Resistance in Bladder Cancer Cells with Cancer Stem Cell-Like Properties.
    Int J Mol Sci. 2021;23.
    PubMed    
    Abstract available

  126. JAGUSIAK A, Gosiewski T, Romaniszyn D, Lasota M, et al
    Antibacterial Therapy by Ag(+) Ions Complexed with Titan Yellow/Congo Red and Albumin during Anticancer Therapy of Urinary Bladder Cancer.
    Int J Mol Sci. 2021;23.
    PubMed    
    Abstract available

  127. VAN HATTUM JW, de Ruiter BM, Oddens JR, Hulshof MCCM, et al
    Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer-A Review.
    Cancers (Basel). 2021;14.
    PubMed    
    Abstract available

  128. MAZZA C, Gaydou V, Eymard JC, Birembaut P, et al
    Identification of Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer by Fourier-Transform Infrared Micro-Imaging.
    Cancers (Basel). 2021;14.
    PubMed    
    Abstract available

  129. YANG X, Wei X, Yi C, Yang Y, et al
    Long Noncoding RNA HAND2-AS1 Suppresses Cell Proliferation, Migration, and Invasion of Bladder Cancer via miR-17-5p/KLF9 Axis.
    DNA Cell Biol. 2022 Jan 10. doi: 10.1089/dna.2021.0637.
    PubMed    
    Abstract available

  130. CHEN WH, Yu KJ, Jhou JW, Pang HH, et al
    Glucose/Glutathione Co-triggered Tumor Hypoxia Relief and Chemodynamic Therapy to Enhance Photothermal Therapy in Bladder Cancer.
    ACS Appl Bio Mater. 2021;4:7485-7496.
    PubMed    
    Abstract available

  131. CHEN D, Ye Y, Guo S, Yao K, et al
    Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.
    Front Mol Biosci. 2021;8:800945.
    PubMed    
    Abstract available

  132. ZHANG F, Feng D, Wang X, Gu Y, et al
    An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer.
    Front Mol Biosci. 2021;8:780329.
    PubMed    
    Abstract available

  133. LIU J, Wang J, Wu M, Zhang W, et al
    Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
    Front Med (Lausanne). 2021;8:757432.
    PubMed    
    Abstract available

  134. ZHENG X, Liao X, Nie L, Lin T, et al
    LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients.
    Front Cell Dev Biol. 2021;9:748280.
    PubMed    
    Abstract available

  135. WANG J, Peng X, Li R, Liu K, et al
    Evaluation of Serum miR-17-92 Cluster as Noninvasive Biomarkers for Bladder Cancer Diagnosis.
    Front Oncol. 2021;11:795837.
    PubMed    
    Abstract available

  136. TAN S, Fu L, Dong Q
    AATF is Overexpressed in Human Bladder Cancer and Regulates Chemo-Sensitivity Through Survivin.
    Onco Targets Ther. 2021;14:5493-5505.
    PubMed    
    Abstract available

  137. SANTOS HJSP, Matheus LHG, Silva A, Dalmazzo SV, et al
    Indoleamine 2,3-Dioxygenase-1 Expression is Changed During Bladder Cancer Cell Invasion.
    Int J Tryptophan Res. 2022;15:11786469211065612.
    PubMed    
    Abstract available

  138. JIN S, Zeng H, Liu Z, Jin K, et al
    Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients.
    Ann Surg Oncol. 2022 Jan 9. pii: 10.1245/s10434-021-11155.
    PubMed    
    Abstract available

  139. SUN Y, Guan Z, Sheng Q, Duan W, et al
    N-myristoyltransferase-1 deficiency blocks myristoylation of LAMTOR1 and inhibits bladder cancer progression.
    Cancer Lett. 2022;529:126-138.
    PubMed    
    Abstract available

  140. CROCETTO F, Barone B, Ferro M, Busetto GM, et al
    Liquid biopsy in bladder cancer: State of the art and future perspectives.
    Crit Rev Oncol Hematol. 2022;170:103577.
    PubMed    
    Abstract available

  141. WILKINS A, Hall E, Lewis R, Gribble H, et al
    RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy.
    Clin Oncol (R Coll Radiol). 2022 Jan 5. pii: S0936-6555(21)00518.
    PubMed    


  142. FUJIZUKA Y, Suzuki K, Sawada T, Suto Y, et al
    [Malignant Central Nervous System Lymphoma after Radical Total Cystectomy : A Diagnostic Challenge].
    Hinyokika Kiyo. 2021;67:539-542.
    PubMed    
    Abstract available

  143. SUZUKI R, Kohei N, Kiyozuka K
    [A Case of Advanced Bladder Carcinoma Treated by Third-Line Gemcitabine and Paclitaxel Chemotherapy].
    Hinyokika Kiyo. 2021;67:533-537.
    PubMed    
    Abstract available

  144. COHEN S, Gal J, Freifeld Y, Khoury S, et al
    Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy Complications.
    Nutrients. 2021;13.
    PubMed    
    Abstract available

  145. HAGHSHENAS MR, Hosseini SR, Fattahi MJ, Malekzadeh M, et al
    Elevated IL-37 Serum Levels in Patients with Transitional Cell Carcinoma of Bladder.
    Iran J Immunol. 2021;18:346-353.
    PubMed    
    Abstract available

  146. XU G, Li J, Yu L
    miR-19a-3p Promotes Tumor-Relevant Behaviors in Bladder Urothelial Carcinoma via Targeting THBS1.
    Comput Math Methods Med. 2021;2021:2710231.
    PubMed    
    Abstract available

  147. TAPAK L, Kosorok MR, Sadeghifar M, Hamidi O, et al
    Regularized Weighted Nonparametric Likelihood Approach for High-Dimension Sparse Subdistribution Hazards Model for Competing Risk Data.
    Comput Math Methods Med. 2021;2021:5169052.
    PubMed    
    Abstract available

  148. KHRIGUIAN J, Patrocinio H, Andonian S, Aprikian A, et al
    Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma.
    Pract Radiat Oncol. 2022;12:e34-e39.
    PubMed    
    Abstract available

  149. SINGH PK, Bhatt MLB, Singh P, Rath SK, et al
    Frequent expression of a novel cancer testis antigen, protein kinase human monopolar spindle 1 (hMps1/TTK) in human urinary bladder transitional cell carcinoma.
    Drug Discov Ther. 2021;15:204-209.
    PubMed    
    Abstract available

  150. CHEN TJ, Dehghanian SZ, Chan TC, He HL, et al
    High G protein subunit beta 4 protein level is correlated to poor prognosis of urothelial carcinoma.
    Med Mol Morphol. 2021;54:356-367.
    PubMed    
    Abstract available

  151. KAPETANAKIS V, Prawitz T, Schlichting M, Ishak KJ, et al
    How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments.
    Value Health. 2021;24:1137-1144.
    PubMed    
    Abstract available

  152. GALSKY MD, Balar AV, Black PC, Campbell MT, et al
    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.
    J Immunother Cancer. 2021;9.
    PubMed    
    Abstract available

  153. ANAMI T, Komohara Y, Miura Y, Yamanaka K, et al
    High T-cell infiltration in tumor tissue and younger age predict the response to pembrolizumab in recurrent urothelial cancer.
    Med Mol Morphol. 2021;54:316-323.
    PubMed    
    Abstract available

  154. WU B, Jiang X, Huang Y, Ying X, et al
    Integrated analysis of mRNA-m(6)A-protein profiles reveals novel insights into the mechanisms for cadmium-induced urothelial transformation.
    Biomarkers. 2021;26:499-507.
    PubMed    
    Abstract available

  155. TAN WS, Kelly JD
    Is delay to radical cystectomy following BCG failure oncologically safe?
    Nat Rev Urol. 2021;18:323-324.
    PubMed    


  156. TODENHOFER T, Maas M, Ketz M, Kossack N, et al
    Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB.
    World J Urol. 2021;39:2953-2960.
    PubMed    
    Abstract available

  157. SANCHEZ DJ, Missiaen R, Skuli N, Steger DJ, et al
    Cell-Intrinsic Tumorigenic Functions of PPARgamma in Bladder Urothelial Carcinoma.
    Mol Cancer Res. 2021;19:598-611.
    PubMed    
    Abstract available

  158. BERRIDGE C, Kailavasan M, Athanasiadis G, Gkentzis A, et al
    Endoscopic surgical simulation using low-fidelity and virtual reality transurethral resection simulators in urology simulation boot camp course: trainees feedback assessment study.
    World J Urol. 2021;39:3103-3107.
    PubMed    
    Abstract available

  159. SURCEL C, Mirvald C, Tsaur I, Borgmann H, et al
    Contemporary role of palliative cystoprostatectomy or pelvic exenteration in advanced symptomatic prostate cancer.
    World J Urol. 2021;39:2483-2490.
    PubMed    
    Abstract available

  160. RODLER S, Buchner A, Ledderose ST, Eismann L, et al
    Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy?
    World J Urol. 2021;39:2537-2543.
    PubMed    
    Abstract available

  161. MITRA S, Purkait S, Das MK
    Unilateral axillary lymph node metastasis from small cell neuroendocrine carcinoma of the urinary bladder.
    Cytopathology. 2021;32:371-373.
    PubMed    


  162. HACEK J, Brisuda A, Babjuk M, Zamecnik J, et al
    Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021;165:316-321.
    PubMed    
    Abstract available

  163. FREUDENBURG E, Shan Y, Martinez A, Srinivasan A, et al
    Geographic distribution of racial differences in mortality in muscle-invasive bladder cancer patients: an opportunity for improvement.
    Cancer Causes Control. 2022 Jan 20. pii: 10.1007/s10552-022-01553.
    PubMed    
    Abstract available

  164. AMINOLTEJARI K, Kulkarni G, Mason R
    Practice-changing publications: Muscle-invasive bladder cancer.
    Can Urol Assoc J. 2021 Aug 26. pii: cuaj.7733. doi: 10.5489/cuaj.7733.
    PubMed    


  165. SHIH HJ, Lin KH, Wen YC, Fan YC, et al
    Increased risk of bladder cancer in young adult men with hyperlipidemia: A population-based cohort study.
    Medicine (Baltimore). 2021;100:e28125.
    PubMed    
    Abstract available

  166. MENG X, Hu H, Wang Y, Feng C, et al
    Accuracy and Challenges in the Vesical Imaging-Reporting and Data System for Staging Bladder Cancer.
    J Magn Reson Imaging. 2022 Jan 20. doi: 10.1002/jmri.28064.
    PubMed    
    Abstract available

  167. ZHANG Z, Zhao H, Zhou G, Han R, et al
    Circ_0002623 promotes bladder cancer progression by regulating the miR-1276/SMAD2 axis.
    Cancer Sci. 2022 Jan 20. doi: 10.1111/cas.15274.
    PubMed    
    Abstract available

  168. XUAN L, Hu JH, Bi R, Liu SQ, et al
    Andrographolide Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer Cells by Interfering with NF-kappaB and PI3K/AKT Signaling In Vitro and In Vivo.
    Chin J Integr Med. 2022 Jan 19. pii: 10.1007/s11655-022-3464.
    PubMed    
    Abstract available

  169. MUSAT MG, Kwon CS, Masters E, Sikirica S, et al
    Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR).
    Clinicoecon Outcomes Res. 2022;14:35-48.
    PubMed    
    Abstract available

  170. MATSUI Y
    [. The Development Status of the Novel Therapeutic Strategies against Non-Muscle Invasive Bladder Cancer -The Introduction of On-Going or Completed Clinical Trials].
    Gan To Kagaku Ryoho. 2022;49:39-42.
    PubMed    


  171. MIYAKE M
    [. Clinical Evidence and Biological Mechanism of BCG Failure in Patients with Non-Muscle Invasive Bladder Cancer].
    Gan To Kagaku Ryoho. 2022;49:33-38.
    PubMed    


  172. FUKUHARA H, Inoue K
    [. Diagnosis and Therapy for Non-Muscle Invasive Bladder Cancer Using Photodynamic Technique].
    Gan To Kagaku Ryoho. 2022;49:29-32.
    PubMed    


  173. NISHIYAMA H
    [Urological Cancer Non-Muscle Invasive Bladder Cancer- Update of Diagnosis and Treatment].
    Gan To Kagaku Ryoho. 2022;49:28.
    PubMed    


  174. KALAYARASAN R, Narayanan S, James M
    Robotic fluorescence-guided anatomical segment IVb and V liver resection with radical lymphadenectomy for gall bladder cancer.
    J Minim Access Surg. 2022 Jan 6. pii: 335071. doi: 10.4103.
    PubMed    
    Abstract available

  175. GABRIELSON AT, Daniels MJ, Rowe J, Alam R, et al
    Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials.
    Urol Oncol. 2022 Jan 16. pii: S1078-1439(21)00536.
    PubMed    
    Abstract available

  176. ZHANG Z, Liang Z, Li D, Wang L, et al
    Development of a CAFs-related gene signature to predict survival and drug response in bladder cancer.
    Hum Cell. 2022 Jan 19. pii: 10.1007/s13577-022-00673.
    PubMed    
    Abstract available

  177. YU Y, Zeng H, Jin K, You R, et al
    Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    Cancer Immunol Immunother. 2022 Jan 18. pii: 10.1007/s00262-022-03153.
    PubMed    
    Abstract available

  178. NISHIMURA K, Nishio K, Hirosuna K, Komura K, et al
    Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.
    J Immunother Cancer. 2022;10.
    PubMed    
    Abstract available

  179. VENKAT S, Lewicki PJ, Khan AI, Gaffney C, et al
    Sociodemographic Disparities in Access to Chemotherapy for Bladder Cancer.
    Clin Genitourin Cancer. 2021 Dec 24. pii: S1558-7673(21)00248.
    PubMed    
    Abstract available

  180. ISALI I, McClellan P, Calaway A, Prunty M, et al
    Gene network profiling in muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Urol Oncol. 2022 Jan 15. pii: S1078-1439(21)00484.
    PubMed    
    Abstract available

  181. YANG C, Wu S, Mou Z, Zhou Q, et al
    Exosome derived circTRPS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironment through modulating reactive oxygen species equilibrium via GLS1 mediated glutamine metabolism alteration.
    Mol Ther. 2022 Jan 13. pii: S1525-0016(22)00022.
    PubMed    
    Abstract available

  182. LEONI C, Paradiso FV, Foschi N, Tedesco M, et al
    Prevalence of bladder cancer in Costello syndrome: new insights to drive clinical decision-making.
    Clin Genet. 2022 Jan 17. doi: 10.1111/cge.14111.
    PubMed    
    Abstract available

  183. GUERRERO-RAMOS F, Gonzalez-Padilla DA, Gonzalez-Diaz A, de la Rosa-Kehrmann F, et al
    Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.
    World J Urol. 2022 Jan 17. pii: 10.1007/s00345-022-03928.
    PubMed    
    Abstract available

  184. THOMAS PB, Perera MPJ, Alinezhad S, Joshi A, et al
    Culture of Bladder Cancer Organoids as Precision Medicine Tools.
    J Vis Exp. 2021;.
    PubMed    
    Abstract available

  185. ADEYELU TT, Moya-Garcia AA, Orengo C
    Exploiting protein family and protein network data to identify novel drug targets for bladder cancer.
    Oncotarget. 2022;13:105-117.
    PubMed    
    Abstract available

  186. BAN D, Lu W, Lu Z, Li B, et al
    Effects of radical cystectomy combined with GC chemotherapy in the treatment of invasive bladder cancer and its influence on the incidence of adverse reactions.
    Am J Transl Res. 2021;13:13845-13853.
    PubMed    
    Abstract available

  187. XU Y, Lou J, Gao Z, Zhan M, et al
    Computed Tomography Image Features under Deep Learning Algorithm Applied in Staging Diagnosis of Bladder Cancer and Detection on Ceramide Glycosylation.
    Comput Math Methods Med. 2022;2022:7979523.
    PubMed    
    Abstract available

  188. SINGH PK, Bhatt MLB, Singh P, Rath SK, et al
    CASC5 is a potential cancer-testis gene in human urinary bladder transitional cell carcinoma.
    Drug Discov Ther. 2021;15:331-336.
    PubMed    
    Abstract available

  189. MUHLBAUER J, Klotz D, Buttner S, Stein R, et al
    Bladder cancer in patients with neurogenic bladder disorder: a comparative study of different etiologies.
    World J Urol. 2022 Jan 15. pii: 10.1007/s00345-021-03922.
    PubMed    
    Abstract available

  190. WANG SC, Yu CY, Wu YC, Chang YC, et al
    Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
    Cancer Lett. 2022;530:8-15.
    PubMed    
    Abstract available

  191. OSWALD D, Pallauf M, Herrmann TRW, Netsch C, et al
    [Transurethral resection of bladder tumors (TURBT)].
    Urologe A. 2022;61:71-82.
    PubMed    
    Abstract available

  192. LAUKHTINA E, Sari Motlagh R, Mori K, Katayama S, et al
    Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes.
    Crit Rev Oncol Hematol. 2022;169:103570.
    PubMed    
    Abstract available

  193. KOLLI RT, Xu Z, Panduri V, Taylor JA, et al
    Differential Gene Expression in Bladder Tumors from Workers Occupationally Exposed to Arylamines.
    Biomed Res Int. 2021;2021:2624433.
    PubMed    
    Abstract available

  194. MORRISS S, Zargar H, Dias BH
    Management of the Distal Ureter During Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Comprehensive Review of Literature.
    Urol J. 2021;18:585-599.
    PubMed    
    Abstract available

  195. ALSYOUF M, Djaladat H, Daneshmand S
    An emerging role for immuno-nutrition in patients undergoing radical cystectomy.
    Nat Rev Urol. 2022;19:1-2.
    PubMed    


  196. AGARWAL PK, Sfakianos JP, Feldman A, Tagawa ST, et al
    A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer.
    Urol Oncol. 2021;39:528-547.
    PubMed    
    Abstract available

  197. FELDMAN AS, Lokeshwar V, Lin DW
    A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers.
    Urol Oncol. 2021;39:602-617.
    PubMed    
    Abstract available

  198. TAYEH GA, Alkassis M, Semaan A, Khalil N, et al
    Neoadjuvant PARPi for urothelial carcinoma: between lifeline and desperation.
    Future Oncol. 2021;17:3281-3283.
    PubMed    


  199. BASIRI A, Soltani MH, Shakhssalim N, Shemshaki HR, et al
    Single Umbilical Stoma for Bilateral Ureterostomy after Radical Cystectomy.
    Urol J. 2021;18:646-651.
    PubMed    
    Abstract available

  200. OGUNBONA OB, Matoso A, Cheng L, Shen S, et al
    Metastatic urothelial carcinoma to the brain, spinal cord and spine: A contemporary multi-institutional clinicopathologic analysis of 24 cases.
    Pathol Res Pract. 2021;224:153537.
    PubMed    
    Abstract available

  201. VARELA DOS SANTOS M, Pacheco J, Barroca H
    Guar cells in urine cytology: Two case reports and literature review.
    Cytopathology. 2021;32:671-673.
    PubMed    


  202. TREGUNNA R
    Combination treatment in advanced urothelial carcinoma.
    Nat Rev Urol. 2021;18:383.
    PubMed    


  203. FUKUOKAYA W, Kimura T, Yanagisawa T, Kimura S, et al
    Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma.
    Cancer Immunol Immunother. 2022;71:229-236.
    PubMed    
    Abstract available

  204. OKUDA C, Kyotake A, Nakamura A, Itoh T, et al
    Quantitative cytomorphological comparison of SurePath and ThinPrep liquid-based cytology using high-grade urothelial carcinoma cells.
    Cytopathology. 2021;32:654-659.
    PubMed    
    Abstract available

  205. ABDULLGAFFAR B, Hotait H
    The value of intercluster single cell streaks, triplet signet ring cells, and a two-cell population in urine small cell neuroendocrine carcinoma.
    Cytopathology. 2021;32:700-704.
    PubMed    


  206. ZEUSCHNER P, Vollmer SG, Linxweiler J, Wagenpfeil G, et al
    Robot-assisted versus open radical nephroureterectomy for urothelial carcinoma of the upper urinary tract: A retrospective cohort study across ten years.
    Surg Oncol. 2021;38:101607.
    PubMed    
    Abstract available

  207. GIERTH M, Breyer J, Zeman F, Fritsche HM, et al
    The HELENA study: Hexvix((R))-TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority study.
    World J Urol. 2021;39:3799-3805.
    PubMed    
    Abstract available

  208. UYSAL D, Egen L, Grilli M, Wessels F, et al
    Impact of perioperative blood transfusions on oncologic outcomes after radical cystectomy: A systematic review and meta-analysis of comparative studies.
    Surg Oncol. 2021;38:101592.
    PubMed    
    Abstract available

  209. XIAO CX, Zhang W, Lin BX
    The Effect of Action Research on Neobladder Function Training in Patients with Orthotopic Ileal Neobladders: A Prospective Cohort Study.
    Urol J. 2021;18:525-529.
    PubMed    
    Abstract available

  210. WU YR, Lee YC, Li WM, Hsu WC, et al
    High Transaldolase 1 expression predicts poor survival of patients with upper tract urothelial carcinoma.
    Pathol Int. 2021;71:463-470.
    PubMed    
    Abstract available

  211. XU H, Genega EM, Zhuang L, Zhou M, et al
    High-grade Urothelial Carcinoma with Malignant Melanocytic Differentiation.
    Int J Surg Pathol. 2021;29:794-797.
    PubMed    
    Abstract available

  212. MARIAPPAN P
    Attention to detail and a permissive set-up: crucial for an effective TURBT.
    Nat Rev Urol. 2021;18:253-254.
    PubMed    


  213. BANSAL P, Dwivedi DK, Hatwal D, Sharma P, et al
    Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
    Anticancer Agents Med Chem. 2021;21:2478-2486.
    PubMed    
    Abstract available

  214. WU J, Chen S, Wu X, Mao W, et al
    Trends of incidence and prognosis of upper tract urothelial carcinoma.
    Bosn J Basic Med Sci. 2021;21:607-619.
    PubMed    
    Abstract available

  215. EL-GEDAMY M, El-Khayat Z, Abol-Enein H, El-Said A, et al
    Rs-1884444 G/T variant in IL-23 receptor is likely to modify risk of bladder urothelial carcinoma by regulating IL-23/IL-17 inflammatory pathway.
    Cytokine. 2021;138:155355.
    PubMed    
    Abstract available

  216. BRUNELLI M, Tafuri A, Cima L, Cerruto MA, et al
    MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
    J Clin Pathol. 2022;75:39-44.
    PubMed    
    Abstract available

  217. TAMBARO R, Napoli MD, Pisano C, Cecere SC, et al
    From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer.
    Immunotherapy. 2021;13:67-77.
    PubMed    
    Abstract available

  218. POSIELSKI N MD, Koenig H MPH, Ho O PhD, Porter C MD, et al
    Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.
    Oncology (Williston Park). 2022;36:21-33.
    PubMed    
    Abstract available

  219. GONG J
    Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer.
    Oncology (Williston Park). 2022;36:30-31.
    PubMed    
    Abstract available

  220. ZARGAR P, Koochakkhani S, Hassanzadeh M, Ashouri Taziani Y, et al
    Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy.
    Mol Biol Rep. 2022 Jan 28. pii: 10.1007/s11033-021-07087.
    PubMed    
    Abstract available

  221. LIU Q
    Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer.
    Front Genet. 2022;12:825109.
    PubMed    
    Abstract available

  222. LEE YC, Tsai KW, Liao JB, Kuo WT, et al
    High expression of tight junction protein 1 as a predictive biomarker for bladder cancer grade and staging.
    Sci Rep. 2022;12:1496.
    PubMed    
    Abstract available

  223. KOKOROVIC A, Ory J, Saad F
    Emerging treatment options for bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
    Curr Opin Support Palliat Care. 2022;16:48-53.
    PubMed    
    Abstract available

  224. WEI W, Rong Y, Sanhe L, Chunxiu Y, et al
    Single-cell sequencing and its applications in bladder cancer.
    Expert Rev Mol Med. 2022;24:e6.
    PubMed    
    Abstract available

  225. YU X, Wu T, Liao B, Du Z, et al
    Anticancer potential of corilagin on T24 and TSGH 8301 bladder cancer cells via the activation of apoptosis by the suppression of NF-kappaB-induced P13K/Akt signaling pathway.
    Environ Toxicol. 2022 Jan 27. doi: 10.1002/tox.23472.
    PubMed    
    Abstract available

  226. BALASUBRAMANIAN A, Gunjur A, Weickhardt A, Papa N, et al
    Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.
    World J Urol. 2022 Jan 27. pii: 10.1007/s00345-021-03908.
    PubMed    
    Abstract available

  227. KOSTYEV F, Bondar O, Chystiakov R, Lysenko V, et al
    The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer.
    Cent European J Urol. 2021;74:496-502.
    PubMed    
    Abstract available


  228. Erratum: The Usefulness of the Modified Frailty Index for Muscle-Invasive Bladder Cancer Patients Treated with Radical Cystectomy: Erratum.
    Curr Urol. 2021;15:253.
    PubMed    
    Abstract available


  229. Erratum: In vivo photobleaching kinetics and epithelial biodistribution of hexylaminolevulinate-induced protoporphyrin IX in rat bladder cancer: Erratum.
    Curr Urol. 2021;15:246.
    PubMed    
    Abstract available

  230. WU G, Liang H, Nan H, Shao Z, et al
    One-Step In Situ Self-Assembly of Biodegradable Films for Long-Term Intravesical Bladder Cancer Therapy.
    ACS Appl Bio Mater. 2022 Jan 26. doi: 10.1021/acsabm.1c01186.
    PubMed    
    Abstract available

  231. MOCHIZUKI Y, Tsuchiya M, Oyama J, Wada A, et al
    Left supraclavicular (Virchow's) node metastasis detected before primary infradiaphragmatic tumor: a case series.
    J Med Case Rep. 2022;16:33.
    PubMed    
    Abstract available

  232. STERNSCHUSS M, Sarfaty M
    [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
    Harefuah. 2022;161:49-54.
    PubMed    
    Abstract available

  233. WU Y, Zhang Z, Liu Y, Shi G, et al
    The Application Effect of Traditional Chinese Medicine Nursing on General Anesthesia Combined with Epidural Anesthesia and Electric Resection for the Treatment of Bladder Cancer and Its Influence on Tumor Markers.
    Evid Based Complement Alternat Med. 2022;2022:7178711.
    PubMed    
    Abstract available

  234. SYMEONIDIS A, Tsikopoulos I, Symeonidis EN, Tsifountoudis I, et al
    More than meets the eye: A case of synchronous ipsilateral clear cell renal cell carcinoma and urothelial carcinoma of the pelvicalyceal system and literature review.
    Acta Biomed. 2022;92:e2021380.
    PubMed    
    Abstract available

  235. CHIANG CH, Chiang CH, Chiang CH
    Re: Ekaterina Laukhtina, Sung Ryul Shim, Keiichiro Mori, et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2021;4:927-42: Considerations for
    Eur Urol Oncol. 2022 Jan 21. pii: S2588-9311(22)00002.
    PubMed    


  236. DOWNES MR, Lajkosz K, Kuk C, Gao B, et al
    The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes.
    Pathology. 2022 Jan 21. pii: S0031-3025(21)00545.
    PubMed    
    Abstract available

  237. RISTIC PETROVIC A, Stokanovic D, Stojnev S, Potic Floranovic M, et al
    The Association between NOTCH3 expression and the clinical outcome in the urothelial bladder cancer patients.
    Bosn J Basic Med Sci. 2022 Jan 24. doi: 10.17305/bjbms.2021.6767.
    PubMed    
    Abstract available

  238. YANG R, Zhu D, Howard LE, De Hoedt A, et al
    Context-Based Identification of Muscle Invasion Status in Patients With Bladder Cancer Using Natural Language Processing.
    JCO Clin Cancer Inform. 2022;6:e2100097.
    PubMed    
    Abstract available

  239. JIN S, Zeng H, Liu Z, Jin K, et al
    ASO Visual Abstract: Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients.
    Ann Surg Oncol. 2022 Jan 24. pii: 10.1245/s10434-021-11262.
    PubMed    


  240. SZYMANSKA B, Sawicka E, Jurkowska K, Matuszewski M, et al
    The relationship between interleukin-13 and angiogenin in patients with bladder cancer.
    J Physiol Pharmacol. 2021;72.
    PubMed    
    Abstract available

  241. KOTHA NV, Kumar A, Nelson TJ, Qiao EM, et al
    Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation.
    Adv Radiat Oncol. 2021;7:100836.
    PubMed    
    Abstract available

  242. XIE C, Yuan X, Chen SH, Liu ZY, et al
    Successful response to camrelizumab in metastatic bladder cancer: A case report.
    World J Clin Cases. 2022;10:254-259.
    PubMed    
    Abstract available

  243. ZENG S, Ying Y, Yu X, Wang L, et al
    Impact of previous, simultaneous or intravesical recurrence bladder cancer on prognosis of upper tract urothelial carcinoma after nephroureterectomy: a large population-based study.
    Transl Androl Urol. 2021;10:4365-4375.
    PubMed    
    Abstract available

  244. ZHANG Z, Li Q, Li A, Wang F, et al
    Identifying a hypoxia related score to predict the prognosis of bladder cancer: a study with The Cancer Genome Atlas (TCGA) database.
    Transl Androl Urol. 2021;10:4353-4364.
    PubMed    
    Abstract available

  245. WANG H, Zuo Y, Ding M, Ke C, et al
    Erratum: LASS2 inhibits growth and invasion of bladder cancer by regulating ATPase activity.
    Oncol Lett. 2022;23:69.
    PubMed    
    Abstract available

  246. WU K, Zeng J, Shi X, Xie J, et al
    Targeting TIGIT Inhibits Bladder Cancer Metastasis Through Suppressing IL-32.
    Front Pharmacol. 2022;12:801493.
    PubMed    
    Abstract available

  247. ANWAR I, Pandith AA, Wani MS, Mir H, et al
    Analysis of MNS16A VNTR polymorphic sequence variations of the TERT gene and associated risk for development of bladder cancer.
    Curr Urol. 2021;15:225-230.
    PubMed    
    Abstract available

  248. ERAY A, Erkek-Ozhan S
    Classification of bladder cancer cell lines according to regulon activity.
    Turk J Biol. 2021;45:656-666.
    PubMed    
    Abstract available

  249. VAN HAUEN MB, Maibom SL, Thind PO, Martin Poulsen A, et al
    Risk of recurrence and long-term mortality following radical cystectomy for bladder cancer.
    Scand J Urol. 2022 Jan 24:1-6. doi: 10.1080/21681805.2022.2028897.
    PubMed    
    Abstract available

  250. ZHANG Z, Wang C, Liu T, Tang Z, et al
    miRNA-182-5p promotes human bladder cancer proliferation and migration through the FOXF2/SHH axis.
    Neoplasma. 2022 Jan 25. pii: 210903N1266. doi: 10.4149/neo_2021_210903N1266.
    PubMed    
    Abstract available

  251. WIECZOREK E, Jablonowski Z, Lesicka M, Jablonska E, et al
    Genetic contributions of MHC class I antigen processing and presentation pathway to bladder cancer risk and recurrence.
    Neoplasma. 2022 Jan 25. pii: 210805N1113. doi: 10.4149/neo_2021_210805N1113.
    PubMed    
    Abstract available

  252. SZUCS E, Lukacs N, Budai A, Seres E, et al
    Actinomycosis mimicking urachal cancer
    Orv Hetil. 2022;163:157-160.
    PubMed    
    Abstract available

  253. BORHANI S, Borhani R, Kajdacsy-Balla A
    Artificial intelligence: A promising frontier in bladder cancer diagnosis and outcome prediction.
    Crit Rev Oncol Hematol. 2022 Jan 19:103601.
    PubMed    
    Abstract available

  254. MARTINS-LIMA C, Miranda-Goncalves V, Lobo J, Constancio V, et al
    Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression.
    Cell Oncol (Dordr). 2022 Jan 22. pii: 10.1007/s13402-021-00657.
    PubMed    
    Abstract available

  255. ZHANG G, Wu Z, Zhang X, Xu L, et al
    CT-based radiomics to predict muscle invasion in bladder cancer.
    Eur Radiol. 2022 Jan 22. pii: 10.1007/s00330-021-08426.
    PubMed    
    Abstract available

  256. WU Z, Xia C, Zhang C, Tang D, et al
    Adeno-associated virus-delivered alpha synuclein inhibits bladder cancer growth via the p53/p21 signaling pathway.
    Cancer Gene Ther. 2022 Jan 21. pii: 10.1038/s41417-022-00425.
    PubMed    
    Abstract available

  257. ARAFA A, Ewis A, Eshak E
    Chronic exposure to nitrate in drinking water and the risk of bladder cancer: a meta-analysis of epidemiological evidence.
    Public Health. 2022;203:123-129.
    PubMed    
    Abstract available

  258. LIU D, Wang S, Wang J
    The effect of CT high-resolution imaging diagnosis based on deep residual network on the pathology of bladder cancer classification and staging.
    Comput Methods Programs Biomed. 2022;215:106635.
    PubMed    
    Abstract available

  259. LAUKHTINA E, Shim SR, Mori K, D'Andrea D, et al
    Corrigendum to "Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis" [Eur Urol Oncol 2021;4:927-42].
    Eur Urol Oncol. 2022 Jan 19. pii: S2588-9311(22)00004.
    PubMed    


  260. CHEN JQ, Salas LA, Wiencke JK, Koestler DC, et al
    Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes.
    Clin Epigenetics. 2022;14:14.
    PubMed    
    Abstract available

  261. KHATAMI A, Salavatiha Z, Razizadeh MH
    Bladder cancer and human papillomavirus association: a systematic review and meta-analysis.
    Infect Agent Cancer. 2022;17:3.
    PubMed    
    Abstract available

  262. CHOI SY, Ha MS, Chi BH, Kim JW, et al
    Neoadjuvant versus adjuvant chemotherapy in bladder cancer: a nationwide cohort study.
    J Cancer Res Clin Oncol. 2022 Jan 21. pii: 10.1007/s00432-022-03926.
    PubMed    
    Abstract available

  263. XIA W, Zhang S, Duan H, Wang C, et al
    The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8(+) T cells in bladder cancer.
    Med Oncol. 2022;39:37.
    PubMed    
    Abstract available

  264. CHEN W, Wang W, Zhang J, Liao G, et al
    Qici Sanling Decoction Suppresses Glutamine Consumption and Bladder Cancer Cell Growth through Inhibiting c-Myc Expression.
    J Oncol. 2022;2022:7985468.
    PubMed    
    Abstract available

  265. WEN L, Zhong G, Ren M
    Increased risk of secondary bladder cancer after radiation therapy for endometrial cancer.
    Sci Rep. 2022;12:1032.
    PubMed    
    Abstract available

  266. XIAO L, Xu C, Lin P, Mu L, et al
    Novel dihydroartemisinin derivative Mito-DHA5 induces apoptosis associated with mitochondrial pathway in bladder cancer cells.
    BMC Pharmacol Toxicol. 2022;23:10.
    PubMed    
    Abstract available

  267. RUTZ J, Maxeiner S, Juengel E, Chun FK, et al
    Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
    Nutrients. 2022;14.
    PubMed    
    Abstract available

  268. MANTICA G, Chierigo F, Malinaric R, Smelzo S, et al
    Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer: What Is the Real Impact of Squamous Cell Carcinoma Variant on Oncological Outcomes?
    Medicina (Kaunas). 2022;58.
    PubMed    
    Abstract available

  269. TSAI IJ, Shen WC, Lee CL, Wang HD, et al
    Machine Learning in Prediction of Bladder Cancer on Clinical Laboratory Data.
    Diagnostics (Basel). 2022;12.
    PubMed    
    Abstract available

  270. MURAKAMI K, Pagano I, Furuya H, Daskivich T, et al
    Clinical Utility of Oncuria, a Multiplexed Liquid Biopsy for the Non-Invasive Detection of Bladder Cancer-A Pilot Study.
    Diagnostics (Basel). 2022;12.
    PubMed    
    Abstract available

  271. RUBIO C, Avendano-Ortiz J, Ruiz-Palomares R, Karaivanova V, et al
    Toward Tumor Fight and Tumor Microenvironment Remodeling: PBA Induces Cell Cycle Arrest and Reduces Tumor Hybrid Cells' Pluripotency in Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed    
    Abstract available

  272. CONSTANTIN T, Pavalean M, Bucur S, Constantin MM, et al
    Retraction: Constantin et al. Animal Models in Bladder Cancer. Biomedicines 2021, 9, 1762.
    Biomedicines. 2022;10.
    PubMed    
    Abstract available

  273. ASANO A, Nishikimi T, Morikami H, Ohashi T, et al
    [A PRIMARY BLADDER ALVEOLAR SOFT PART SARCOMA: A CASE REPORT].
    Nihon Hinyokika Gakkai Zasshi. 2021;112:45-48.
    PubMed    
    Abstract available

  274. TABEI T, Iwai T, Noguchi G, Horiguchi A, et al
    [ARTIFICIAL URINARY SPHINCTER IMPLANTATION AFTER ILEAL NEOBLADDER RECONSTRUCTION: A CASE REPORT].
    Nihon Hinyokika Gakkai Zasshi. 2021;112:34-37.
    PubMed    
    Abstract available

  275. SCHLARBAUM JP, Fenyk J, Miller D, O'Neill LB, et al
    Paraneoplastic Signs in Bladder Transitional Cell Carcinoma: An Unusual Presentation.
    Cutis. 2021;108:E29-E32.
    PubMed    


  276. AFIFY H, Ghoneum A, Almousa S, Abdulfattah AY, et al
    Metabolomic credentialing of murine carcinogen-induced urothelial cancer.
    Sci Rep. 2021;11:22085.
    PubMed    
    Abstract available

  277. DUBOIS J, Sczakiel G
    The human TRAM1 locus expresses circular RNAs.
    Sci Rep. 2021;11:22114.
    PubMed    
    Abstract available

  278. ZHENG S, Carugo D, Mosayyebi A, Turney B, et al
    Fluid mechanical modeling of the upper urinary tract.
    WIREs Mech Dis. 2021;13:e1523.
    PubMed    
    Abstract available

  279. KAWASHIMA A, Yamamoto Y, Sato M, Nakata W, et al
    FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab.
    Sci Rep. 2021;11:21199.
    PubMed    
    Abstract available

  280. YANG WS
    Automated urine sediment analyzers underestimate the severity of hematuria in glomerular diseases.
    Sci Rep. 2021;11:20981.
    PubMed    
    Abstract available

  281. LIU Q, Gong H, Zhu H, Yuan C, et al
    Contrast-Enhanced Ultrasound in the Bladder: Critical Features to Differentiate Occupied Lesions.
    Comput Math Methods Med. 2021;2021:1047948.
    PubMed    
    Abstract available

  282. BRUNETTI B, Foglia A, Savini F, Dondi F, et al
    Inverted urothelial papilloma in a cat.
    Vet Pathol. 2022;59:138-142.
    PubMed    
    Abstract available

  283. HE W, Jin L, Lin FF, Qi XL, et al
    Cavernous lymphangioma of the urinary bladder in an adult woman: an additional case report of a rare lesion and literature review.
    BMC Urol. 2021;21:145.
    PubMed    
    Abstract available

  284. INANAGA S, Igase M, Sakai Y, Tanabe M, et al
    Mismatch repair deficiency in canine neoplasms.
    Vet Pathol. 2021;58:1058-1063.
    PubMed    
    Abstract available

  285. SHUKLA SK, Chandra S, Chauhan N, Sarpal R, et al
    Expression of CD10 in urothelial carcinoma of the bladder and its correlation with histopathological grade, pathological stage, and survival of patients.
    J Cancer Res Ther. 2021;17:887-892.
    PubMed    
    Abstract available

  286. XIE Y, Olkhov-Mitsel E, Alminawi S, Slodkowska E, et al
    Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma.
    Pathol Res Pract. 2021;226:153607.
    PubMed    
    Abstract available

  287. FENG Z, Vuky J
    Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook.
    Oncology (Williston Park). 2021;35:410-420.
    PubMed    
    Abstract available

  288. FENNER A
    Using ctDNA to guide immunotherapy for urothelial cancer.
    Nat Rev Urol. 2021;18:443.
    PubMed    


  289. CHILDS DS, Quevedo JF, Costello BA, Pagliaro LC, et al
    Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series.
    Anticancer Drugs. 2021;32:986-990.
    PubMed    
    Abstract available

  290. SEKER NS, Tekin E, Ozen A, Can C, et al
    Prognostic significance of tumor budding in muscle invasive urothelial carcinomas of the urinary bladder.
    Ann Diagn Pathol. 2021;54:151786.
    PubMed    
    Abstract available

  291. ZHANG X, Chen Y, Yan D, Han J, et al
    TERT Gene rs2736100 and rs2736098 Polymorphisms are Associated with Increased Cancer Risk: A Meta-Analysis.
    Biochem Genet. 2022;60:241-266.
    PubMed    
    Abstract available

  292. FENNER A
    Adjuvant nivolumab improves survival after radical cystectomy.
    Nat Rev Urol. 2021;18:444.
    PubMed    


  293. CHOI E, Waldbillig F, Jeong M, Li D, et al
    Soft Urinary Bladder Phantom for Endoscopic Training.
    Ann Biomed Eng. 2021;49:2412-2420.
    PubMed    
    Abstract available

  294. CHANDLER JB, Colunga M, Celli R, Lithgow MY, et al
    Applicability of the Paris System for veterans: high rates of undiagnosed low-grade urothelial neoplasia.
    J Am Soc Cytopathol. 2021;10:357-365.
    PubMed    
    Abstract available

  295. CHENG L, Lopez-Beltran A, Wang M, Montironi R, et al
    Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
    Mod Pathol. 2021;34:1384-1391.
    PubMed    
    Abstract available

  296. MCALONEY CA, Evans SJM, Hokamp JA, Wellman ML, et al
    Comparison of pathologist review protocols for cytologic detection of prostatic and urothelial carcinomas in canines: A bi-institutional retrospective study of 298 cases.
    Vet Comp Oncol. 2021;19:374-380.
    PubMed    
    Abstract available

  297. SEN A, Kaul A, Kaul R
    Estrogen receptors in human bladder cells regulate innate cytokine responses to differentially modulate uropathogenic E. coli colonization.
    Immunobiology. 2021;226:152020.
    PubMed    
    Abstract available

  298. WOO S, Ghafoor S, Becker AS, Hricak H, et al
    Prognostic Utility of MRI Features in Intradiverticular Bladder Tumor.
    Acad Radiol. 2022;29:219-228.
    PubMed    
    Abstract available

  299. KACZOROWSKI M, Matysiak J, Kielb P, Malkiewicz B, et al
    Nuclear Factor IA Is Down-regulated in Muscle-invasive and High-grade Bladder Cancers.
    Anticancer Res. 2022;42:493-500.
    PubMed    
    Abstract available

  300. HENSLEY PJ, Bree KK, Brooks N, Matulay J, et al
    Time interval from transurethral resection of bladder tumour to bacille Calmette-Guerin induction does not impact therapeutic response.
    BJU Int. 2021;128:634-641.
    PubMed    
    Abstract available

  301. ABOZAID M, Tan WS, Khetrapal P, Baker H, et al
    Recovery of health-related quality of life in patients undergoing robot-assisted radical cystectomy with intracorporeal diversion.
    BJU Int. 2022;129:72-79.
    PubMed    
    Abstract available

  302. VAN HOOGSTRATEN LMC, Witjes JA, Meijer RP, Ripping TM, et al
    Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent.
    BJU Int. 2022 Jan 22. doi: 10.1111/bju.15697.
    PubMed    
    Abstract available

  303. LIU Z, Zeng H, Jin K, Yu Y, et al
    TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Br J Cancer. 2022 Jan 17. pii: 10.1038/s41416-022-01703.
    PubMed    
    Abstract available

  304. BELLAT V, Michel AO, Thomas C, Stokol T, et al
    A urinary drug-disposing approach as an alternative to intravesical chemotherapy for treating non-muscle invasive bladder cancer.
    Cancer Res. 2022 Jan 17. pii: 0008-5472.CAN-21-2897.
    PubMed    
    Abstract available

  305. WANG Y, Zhang Y, Li PC, Guo J, et al
    Development of novel aptamer-based targeted chemotherapy for bladder cancer.
    Cancer Res. 2022 Jan 21. pii: 0008-5472.CAN-21-2691.
    PubMed    
    Abstract available

  306. QIAN J, Huang C, Zhu Z, He Y, et al
    NFE2L3 promotes tumor progression and predicts a poor prognosis of bladder cancer.
    Carcinogenesis. 2022 Jan 12. pii: 6505217. doi: 10.1093.
    PubMed    
    Abstract available

  307. SHENG X, Yan X, Wang L, Shi Y, et al
    Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2021;27:43-51.
    PubMed    
    Abstract available

  308. CHANG E, Weinstock C, Zhang L, Charlab R, et al
    FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2021;27:922-927.
    PubMed    
    Abstract available

  309. ENIKEEV D, Babjuk M, Shpikina A, Shariat S, et al
    En bloc resection for nonmuscle-invasive bladder cancer: selecting a proper laser.
    Curr Opin Urol. 2021 Dec 24. pii: 00042307-900000000-98808.
    PubMed    
    Abstract available

  310. ROUMIGUIE M, Kamat AM, Bivalacqua TJ, Lerner SP, et al
    International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2021 Dec 23. pii: S0302-2838(21)02213.
    PubMed    
    Abstract available

  311. MOSSANEN M, Carvalho FLF, Muralidhar V, Preston MA, et al
    Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
    Eur Urol. 2021 Dec 22. pii: S0302-2838(21)02212.
    PubMed    
    Abstract available

  312. GROBET-JEANDIN E, Pinar U, Roupret M
    Re: Trey Durdin, Alvin Goh, Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol 2021;80:16-7: Transurethral Resection of Bladder Tumor in Diagnosis of Muscle-invasive Bladder Cancer:
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02282.
    PubMed    


  313. SJODAHL G, Abrahamsson J, Holmsten K, Bernardo C, et al
    Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://do
    Eur Urol. 2022 Jan 13. pii: S0302-2838(21)02284.
    PubMed    


  314. DE JONG JJ, Gibb EA
    Re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.10.035: Neoadjuvant Chemotherapy Resp
    Eur Urol. 2022 Jan 13. pii: S0302-2838(21)02281.
    PubMed    


  315. RENTSCH CA, Hayoz S, Cathomas RL
    Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study.
    Eur Urol. 2022 Jan 24. pii: S0302-2838(22)00022.
    PubMed    


  316. HAYAKAWA N, Kikuchi E
    Editorial Comment to Incidence and location of perioperative deep vein thrombosis in patients with bladder cancer undergoing radical cystectomy.
    Int J Urol. 2021 Dec 28. doi: 10.1111/iju.14777.
    PubMed    


  317. SHINDO T
    Editorial Comment from Dr Shindo to Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
    Int J Urol. 2022 Jan 4. doi: 10.1111/iju.14783.
    PubMed    


  318. GRAVESTOCK P, Coulthard N, Veeratterapillay R, Heer R, et al
    Response to Re: Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Jan 1. doi: 10.1111/iju.14780.
    PubMed    


  319. CHEN CS, Li JR, Yang CK, Cheng CL, et al
    Significant predictors of contralateral upper tract recurrence after radical nephroureterectomy for upper tract urothelial carcinoma.
    Int J Urol. 2022;29:69-75.
    PubMed    
    Abstract available

  320. KIJIMA T
    Editorial Comment to Programmed cell death-ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma.
    Int J Urol. 2022;29:91.
    PubMed    


  321. TOMIYAMA E, Fujita K, Hashimoto M, Miyamoto H, et al
    Programmed cell death-ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma.
    Int J Urol. 2022;29:89-90.
    PubMed    


  322. GHOREIFI A, Basin MF, Ghodoussipour S, Bazargani ST, et al
    Perioperative outcomes of goal-directed versus conventional fluid therapy in radical cystectomy with enhanced recovery protocol.
    Int Urol Nephrol. 2021;53:1827-1833.
    PubMed    
    Abstract available

  323. FUNT SA, Lattanzi M, Whiting K, Al-Ahmadie H, et al
    Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
    J Clin Oncol. 2022 Jan 28:JCO2101485. doi: 10.1200/JCO.21.01485.
    PubMed    
    Abstract available

  324. KHALEEL S, Regmi S, Hannah P, Watarai B, et al
    Impact of Preoperative Immunonutrition on Perioperative Outcomes Following Cystectomy. Reply.
    J Urol. 2021;206:1531-1532.
    PubMed    


  325. ALSYOUF M, Djaladat H
    Impact of Preoperative Immunonutrition on Perioperative Outcomes following Cystectomy. Letter.
    J Urol. 2021;206:1530-1531.
    PubMed    


  326. MONAGHAN TF, Wagg AS, Rahman SN, Winer AG, et al
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Letter.
    J Urol. 2022;207:237-238.
    PubMed    


  327. CHESNUT GT, Goh AC
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Reply.
    J Urol. 2022;207:238-239.
    PubMed    


  328. GOLD SA, Kenigsberg AP, Lotan Y
    Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System.
    J Urol. 2022;207:52-60.
    PubMed    
    Abstract available

  329. RAMAN JD, Kavalieris L, Konety B, Porten S, et al
    The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.
    J Urol. 2021;206:1380-1389.
    PubMed    
    Abstract available

  330. YANKELEVICH GR, Dreher PC, Taylor Z, Kim D, et al
    Socio-Environmental Conditions Associated with Geospatial Clusters of Urothelial Carcinoma: A Multi-Institutional Analysis.
    J Urol. 2021;206:1390-1402.
    PubMed    
    Abstract available

  331. FURBERG H, Petruzella S, Whiting K, Stein E, et al
    Association of Biochemically Verified Post-diagnosis Smoking and Non-muscle Invasive Bladder Cancer Recurrence Risk.
    J Urol. 2022 Jan 27:101097JU0000000000002449. doi: 10.1097/JU.0000000000002449.
    PubMed    
    Abstract available

  332. MITRA AP, Cai J, Miranda G, Bhanvadia S, et al
    Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.
    J Urol. 2022;207:302-313.
    PubMed    
    Abstract available

  333. MIEST T, Khanna A, Sharma V, Hensley PJ, et al
    Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma following Radical Cystectomy.
    J Urol. 2022;207:284-292.
    PubMed    
    Abstract available

  334. KOMURA K, Inamoto T, Tsujino T, Matsui Y, et al
    Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents.
    Oncogene. 2021;40:6210-6222.
    PubMed    
    Abstract available

  335. MESSAOUD M, Vercherin P, Chaneliere AF, Mottet N, et al
    [Geriatric assessment and treatment of nonmetastatic muscle-invasive bladder cancer in patients over 75 years of age. Retrospective and multicentric study of 121 cases].
    Prog Urol. 2022 Jan 5. pii: S1166-7087(21)00582.
    PubMed    
    Abstract available

  336. SOOROJEBALLY Y, Surlemont L, Neuzillet Y, Lebret T, et al
    Impact of carcinoma in situ on survival of patients treated by adjuvant chemotherapy after cystectomy.
    Prog Urol. 2022;32:53-60.
    PubMed    
    Abstract available

  337. LEE MS, Shen M, Williams A, Kendrick D, et al
    Retroureteral Small Bowel Herniation Resulting in Bowel Obstruction Following Robotic Cystectomy With Extracorporeal Ileal Conduit.
    Urology. 2021;147:3-6.
    PubMed    


  338. ZHANG Y, Zhu B, Cai Y, Zhu S, et al
    Alteration in glycolytic/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration.
    BMC Cancer. 2022;22:2.
    PubMed    
    Abstract available

  339. HUANG T, Li J, Wang SM
    Core promoter mutation contributes to abnormal gene expression in bladder cancer.
    BMC Cancer. 2022;22:68.
    PubMed    
    Abstract available

  340. ODA S, Fujisawa M, Chunning L, Ito T, et al
    Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder.
    PLoS One. 2021;16:e0254289.
    PubMed    
    Abstract available

  341. AL-EZZI EM, Veitch ZW, Salah SH, Van der Kwast TH, et al
    Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study.
    PLoS One. 2021;16:e0259272.
    PubMed    
    Abstract available

  342. LEMINSKI A, Kaczmarek K, Byrski T, Slojewski M, et al
    Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
    PLoS One. 2021;16:e0259526.
    PubMed    
    Abstract available

  343. SANGSTER AG, Gooding RJ, Garven A, Ghaedi H, et al
    Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer.
    PLoS One. 2022;17:e0259992.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;